Patient demographics for the ALEXANDER study
| Baseline characteristics . | N = 52 (%) . |
|---|---|
| Sex | |
| Female | 20 (38.5) |
| Male | 32 (61.5) |
| Median age in y (range) | 59.0 (27-83) |
| ECOG 0, n (%) | 26 (50) |
| ECOG 1, n (%) | 26 (50) |
| Disease characteristics, n (%) | |
| DLBCL, GCB | 24 (46.2) |
| DLBCL, non-GCB | 12 (23) |
| Transformed follicular lymphoma (tFL) | 10 (19.2) |
| Primary mediastinal LBCL | 1 (2) |
| Transformed nodal marginal zone lymphoma | 1 (2) |
| High grade B-cell lymphoma | 3 (5.8) |
| Molecular subtype, n (%) | |
| No high risk molecular features | 15 (28.8) |
| Double-hit | 14 (26.9) |
| Triple-hit | 5 (9.6) |
| Double-expressor | 8 (15.4) |
| Not done/unknown | 10 (19.2) |
| Disease stage, n (%) | |
| II | 6 (11.5) |
| III | 11 (21.2) |
| IV | 35 (67.3) |
| Baseline IPI, n (%) | |
| Low risk | 8 (15.4) |
| Low-intermediate risk | 16 (30.8) |
| High-intermediate risk | 13 (25) |
| High risk | 10 (19.2) |
| Unknown | 5 (9.6) |
| Prior lines of treatment, n | |
| Median (range) | 3 (1-10) |
| Prior autologous HSCT, n (%) | 16 (30.8) |
| Risk factors | |
| Baseline LDH, median (range) (IU/L) | 243.5 (132-1348) |
| SPD, median (min-max) (cm2) | 18.20 (2.1-260.8) |
| Baseline characteristics . | N = 52 (%) . |
|---|---|
| Sex | |
| Female | 20 (38.5) |
| Male | 32 (61.5) |
| Median age in y (range) | 59.0 (27-83) |
| ECOG 0, n (%) | 26 (50) |
| ECOG 1, n (%) | 26 (50) |
| Disease characteristics, n (%) | |
| DLBCL, GCB | 24 (46.2) |
| DLBCL, non-GCB | 12 (23) |
| Transformed follicular lymphoma (tFL) | 10 (19.2) |
| Primary mediastinal LBCL | 1 (2) |
| Transformed nodal marginal zone lymphoma | 1 (2) |
| High grade B-cell lymphoma | 3 (5.8) |
| Molecular subtype, n (%) | |
| No high risk molecular features | 15 (28.8) |
| Double-hit | 14 (26.9) |
| Triple-hit | 5 (9.6) |
| Double-expressor | 8 (15.4) |
| Not done/unknown | 10 (19.2) |
| Disease stage, n (%) | |
| II | 6 (11.5) |
| III | 11 (21.2) |
| IV | 35 (67.3) |
| Baseline IPI, n (%) | |
| Low risk | 8 (15.4) |
| Low-intermediate risk | 16 (30.8) |
| High-intermediate risk | 13 (25) |
| High risk | 10 (19.2) |
| Unknown | 5 (9.6) |
| Prior lines of treatment, n | |
| Median (range) | 3 (1-10) |
| Prior autologous HSCT, n (%) | 16 (30.8) |
| Risk factors | |
| Baseline LDH, median (range) (IU/L) | 243.5 (132-1348) |
| SPD, median (min-max) (cm2) | 18.20 (2.1-260.8) |
ECOG, Eastern Cooperative Oncology Group; GCB, germinal center B-cell like; HSCT, hematopoietic stem cell transplantation; IPI, international prognostic index.